Mirels' score for upper limb metastatic lesions: do we need a different cutoff for recommending prophylactic fixation?

Katie A. Hoban, BSc (Hons), MBChB, MSc, MRCS (Glasg)\textsuperscript{a,*}, Samantha Downie, BMedSci (Hons), MBChB, MRCS (Ed)\textsuperscript{a}, Douglas J.A. Adamson, MBChB, MD, PhD, FRCP (Edin), FRCR\textsuperscript{b}, James G. MacLean, MBChB, FRCS, FRSEd T&O\textsuperscript{c}, Paul Cool, MD, MMedSc(Res), DipStat, FRCS(Ed), FRCD(Orth)\textsuperscript{d}, Arpit C. Jariwala, MS Orth, MCh Orth Dundee, MRCS Ed, FRCSEd T&O, MD\textsuperscript{e}

\textsuperscript{a}NHS Tayside, Ninewells Hospital & Medical School, Dundee, United Kingdom
\textsuperscript{b}NHS Tayside, Perth Royal Infirmary, Perth, United Kingdom
\textsuperscript{c}The Robert Jones and Agnes Hunt Orthopaedic Hospital, Gobowen, Oswestry, United Kingdom
\textsuperscript{d}Keele University, Keele, Staffordshire, United Kingdom
\textsuperscript{e}University Department of Orthopaedics and Trauma Surgery, Ninewells Hospital & Medical School, University of Dundee, Dundee, United Kingdom

**Hypothesis:** The aim of this study was to investigate the reproducibility, reliability, and accuracy of Mirels’ score in upper limb bony metastatic disease and validate its use in predicting pathologic fractures.

**Methods:** Forty-five patients with upper limb bony metastases met the inclusion criteria (62% male 28/45). The mean age was 69 years (SD 9.5), and the most common primaries were lung (29%, 13/45), followed by prostate and hematological (each 20%, 9/45). The most commonly affected bone was the humerus (76%, 35/45), followed by the ulna (6.5%, 3/45). Mirels’ score was calculated in 32 patients; with plain radiographs at index presentation scored using Mirels’ system by 6 raters. The radiological aspects (lesion size and appearance) were scored twice by each rater (2 weeks apart). Intraobserver and interobserver reliability were calculated using Fleiss’ kappa test. Bland-Altman plots compared the variances of both individual components and the total Mirels’ score.

**Results:** The overall fracture rate of upper limb metastatic lesions was 76% (35/46) with a mean follow-up of 3.6 years (range 11 months-6.8 years). Where time from diagnosis to fracture was known (n = 20), fractures occurred at a median 19 days (interquartile range 60-10), and 80% (16/20) occurred within 3 months of diagnosis. Mirels’ score of >9 did not accurately predict lesions that fractured (fracture rate 11%, 5/46, for Mirels’ >9 vs. 65%, 30/46, for Mirels’ ≤ 8, \(P < .001\)). Sensitivity was 14%, and specificity was 73%. When Mirels’ cutoff was lowered to >7, patients were more likely to fracture than not (48%, 22/46, vs. 28%, 13/46, \(P = .045\)); sensitivity rose to 63%, but specificity fell to 55%.

Kappa values for interobserver variability were \(\kappa = 0.358\) (fair, 95% confidence interval [CI] 0.288-0.429) for lesion size, \(\kappa = 0.107\) (poor, 95% CI 0.02-0.193) for radiological appearance, and \(\kappa = 0.274\) (fair, 95% CI 0.229-0.318) for total Mirels’ score. Values for intraobserver variability were \(\kappa = 0.716\) (good, 95% CI 0.432-0.999) for lesion size, \(\kappa = 0.427\) (moderate, 95% CI 0.195-0.768) for radiological appearance, and \(\kappa = 0.580\) (moderate, 95% CI 0.395-0.765) for total Mirels’ score.

**Conclusions:** This study demonstrates moderate to substantial agreement between and within raters using Mirels’ score on upper limb radiographs. However, Mirels’ score had a poor sensitivity and specificity in predicting upper extremity fractures. Until a more valid scoring system has been developed, based on our study, we recommend a Mirels’ threshold of >7/12 for considering prophylactic fixation of...
The most common cause of destructive bone lesions in the adult population is metastatic bone disease, with the humerus being the second most frequently involved long bone. Pathologic fractures occur in up to 10% of patients with bony metastases and are associated with pain, metabolic disturbance, and a negative impact on quality of life. In addition, presence of a metastatic fracture is a negative prognostic factor and is associated with increased mortality. Accurate prediction of those with bony lesions likely to sustain metastatic fractures could minimize the need for treatment, improve patient outcomes, and make subsequent surgery technically easier.

Mirels’ score, devised in 1989, provides a composite weighted scoring system (from 4 to 12) to predict the likelihood of sustaining a pathologic fracture based on pain, anatomic site, lesion size, and radiographic appearance. Mirels looked retrospectively at 38 patients with 78 long-bone metastases (classified by region as non-weight-bearing bone, weight-bearing bone, or pertrochanteric), with scores ≥8 recommending a 15% fracture risk and ≥9 a 33% fracture risk. It is recommended by the British Orthopaedic Oncology Society that prophylactic fixation should be offered where appropriate, with a threshold of ≥9/12 generally accepted for lower limb lesions. The reproducibility and validity of Mirels’ score in the upper limb is questioned given the load-bearing differences between upper and lower limbs. For instance, Howard et al proposed that the proportion of body weight a patient puts through the affected limb may predict fracture risk. Furthermore, Kronisch et al suggest that using Mirels’ score to predict upper limb pathologic fractures underestimates fracture risk. Mirels’ score does not take into account factors that influence load and functional demand, which has been shown to influence fracture potential. In contrast, other studies have highlighted that up to 20% of impending pathologic fractures may be missed or undergo unnecessary fixation but suggest Mirels’ rating system is a valid, reproducible screening tool to identify impending pathologic humerus fractures when used by physicians with differing levels of experience and specialty, as evidenced by Evans et al.

The aim of this study was to validate the accuracy and reproducibility of the Mirels’ score in predicting metastatic fractures of long bones of the upper limb.

Materials and methods

Study design, data source, and inclusion/exclusion criteria

A retrospective cohort study (January 2013–December 2018) was undertaken in all patients referred to an orthopedic department who had bone metastases of the upper limb long bones. Data were extracted from the Tayside Bony Metastasis Registry database. Patients were included if they had a radiologically visible lesion of any long bone of the upper limb and were confirmed or highly suspicious of metastatic cancer (including myeloma and hematological malignancies such as lymphoma). There were no upper or lower age limits. Patients were followed up until death or until December 2019, whichever was first.

Data extraction

Patient variables (patient age, gender, primary tumor diagnosis, location of metastasis, use of bisphosphonates, analgesic use, and previous radiotherapy [any site]) were extracted from patient electronic case records including follow-up letters to determine outcome.

Raters

Raters comprised 6 clinicians of varying experience and specialty—2 orthopedic registrars (K.A.H. and S.D.), 2 upper limb specialist trauma surgeons (J.G.M. and A.C.J.), an orthopedic oncology surgeon (P.C.), and a consultant clinical oncologist (D.A.).

Mirels’ analysis

For assessment of the radiological parameters of the Mirels’ score, plain radiographs of the limb at presentation were downloaded from the Picture Archive and Communication System server (Insignia, UK) and duplicated in 2 electronic folders. The radiographs were ordered randomly and scored on 2 occasions by 6 investigators (K.A.H., S.D., D.A., P.C., J.G.M., A.C.J.). Each investigator assessed the radiological parameters of the Mirels’ score for each radiograph on 2 occasions 2 weeks apart after reading the original Mirels’ publication. Pain was retrieved from patient records, and a score of 1 was given for site for all lesions, as they all involved the upper limb. The range of possible Mirels’ scores for lesions in this study was therefore 4–10. Our study utilization of the Mirels’ criteria is different to the original paper but is what commonly used in clinical practice.

![Figure 1 Mirels’ score for predicting risk of pathologic fracture in bone metastases of the appendicular skeleton. Initially described by Hilton Mirels in 1989; this figure is reproduced from [Diagnosis and referral of adults with suspected bony metastases, Downie S, Bryden E, Perks F and Simpson AHR, 372, page 7, 2021] with permission from BMJ Publishing Group Ltd.](image-url)
Approvals

Caldicott Guardian approval was secured prospectively (ref IGTCAL3289).

Statistical analysis

Missing data, where present, have been indicated. Where study groups have been directly compared with one another, data set analysis comprised the Chi-square test for categorical variables and the student’s t-test or nonparametric Wilcoxon test as appropriate for continuous variables (significance P < .05). Data were analyzed using IBM SPSS Statistics (v25) (IBM, Armonk, NY, USA), and Fleiss’ kappa test was used to calculate intraobserver and interobserver variability as per a previous study. Assessment of strength of agreement among raters was determined using Cohen’s kappa coefficient as follows: kappa value < 0.20 poor, 0.21-0.40 fair,
Table III
Variation in sensitivity and specificity by Mirels’ threshold for predicting risk of pathologic fracture for upper limb bone metastases.

| Mirels’ cutoff | Sensitivity % | Specificity % | Positive predictive value % | Negative predictive value % |
|----------------|---------------|---------------|----------------------------|----------------------------|
| ≥6             | 91            | 9             | 76                         | 25                         |
| ≥7             | 63            | 55            | 82                         | 32                         |
| ≥8             | 49            | 55            | 77                         | 25                         |
| ≥9             | 14            | 73            | 63                         | 21                         |

Table IV
Table highlighting intraobserver variability in lesion size, radiological appearance, and Mirels’ scores between scoring clinicians.

| Demographic                  | Observation 1 | P value | Observation 2 | P value | Strength of agreement |
|-------------------------------|---------------|---------|---------------|---------|-----------------------|
| Lesion size                   | 0.358 (0.288-0.429) | <.001   | 0.345 (0.276-0.415) | <.001   | Fair                  |
| Radiological appearance       | 0.107 (0.02-0.193)  | .015    | 0.114 (0.024-0.205) | .014    | Poor                  |
| Total Mirels’ score           | 0.274 (0.229-0.318) | <.001   | 0.226 (0.180-0.272) | <.001   | Fair                  |

Results

Upper limb bony metastases study population

From 2013-2018, 10,050 patients were referred to a Scottish regional trauma center (Fig. 2). Of these patients, 2% (207/10,050) had a lesion suspicious for a bony metastasis. Forty-five patients had 46 bony metastases involving the upper limb long bones (45/207, 22%). The mean age was 69 years (range 51-91 years) (Table I). Seventeen (38%) were female, and 28 (62%) were male. The most common primary tumor diagnoses were lung (29%, 13/45), prostate, and hematological (both 20%, 9/45). The location of upper limb metastases is shown in Table I. The humerus was the most commonly affected site (76%, 35/46 lesions), followed by the ulna (65%, 3/46). One patient with breast cancer fractured twice (bilateral humeral fractures).

Overall patient mortality was 29% at 3 months and 73% at 1 year (13/45 and 33/45, respectively). Five patients were still alive with a mean follow-up of 2 years (range 10.7 months to 3 years). The median time from referral for bony metastasis to death for the 40 patients deceased at follow-up was 4.3 months (interquartile range 10.5-2, range 12 days to 3.1 years). For the 35 patients who fractured, the mean time from fracture to death was 6.8 months (SD 5.8, range 12 days to 1.5 years).

Overall rate of progression to surgery was 57% (26/46). Intramedullary nailing was the most common procedure undertaken for upper limb bony metastases (77%, 20/26; Table I).

Fracture rate

The overall fracture rate was 76% (35/46). Where time from lesion diagnosis on radiograph to fracture was known (20/35), lesions occurred at a median 19 days from initial diagnosis (interquartile range 60-10, range 1 day to 2 years) (Table II). Fracture rate rose from 45% at 6 weeks (14/31) to 52% at 3 months (16/31 odds ratio OR 1.3) and 55% at 6 months (17/31 OR 1.5).

A higher Mirels’ score did not predict an increased likelihood of metastatic fracture (mean Mirels’ score for fracture group 7.1, SD 1.4, range 4-10; and no-fracture group 7.2, SD 1.7, range 5-10, respectively) (Table II and Fig. 3). A Mirels’ score of ≥9/12 did not accurately predict patients who would go on to fracture (11%, 5/46, fracture rate for Mirels’ 9 or more vs. 65.2%, 30/46, for Mirels’ 8 or less, P < .001). Almost two-thirds of patients with a Mirels’ score of 8 or less sustained a fracture (65%, 30/46, fracture group vs. 17%, 8/46, no-fracture group, P < .001). The sensitivity of the Mirels’ score in upper limb lesions for scores ≥9 vs. ≤8 was 14% and 73%, respectively (Table III). Those patients with a Mirels’ score of ≥9/12 did not have preponderance to any specific primary tumor diagnosis.

When the Mirels’ cutoff was lowered to ≥7, better prediction of fractures was demonstrated (48%, 22/46, fracture rate for Mirels’ ≥7 vs. 11%, 5/46, for Mirels’ 6 or less, P < .001) (Table III). However, those with a score of 6 or less were still more likely to fracture than not (28%, 13/46, fracture group vs. 13%, 6/46, no-fracture group, P < .001). The sensitivity of the score (lesion size) (Table V).

Intraobserver variability

Table IV demonstrates the kappa values for variability within raters between week 0 and week 2 (intraobserver variability). Kappa values for raters did not significantly differ between baseline (week 0) and week 2 ratings, so the week 0 values were used in the final analysis. There was fair agreement between the raters for lesion size and total Mirels’ score, with poor agreement for radiological appearance (whether lesion was lytic, sclerotic, or mixed on plain radiographs).

Bland-Altman plots were generated to allow visual comparison of individual rater scores (Fig. 4). These graphs demonstrated no intraobserver bias (linear regression coefficients all close to 0), with no difference in variance by Mirels’ score.

Interobserver variability

Kappa values were calculated to determine interobserver variability for all radiological parameters of the Mirels’ score (lesion size, radiological appearance, and total Mirels’ score) (Table V). There was moderate agreement among raters for radiological appearance and total Mirels’ score, and good concordance for lesion size.
(Fig. 5). Linear regression coefficients are close to 0, providing evidence that there is no inter-rater bias.

**Discussion**

**Patient cohort and demographics**

In concordance with the published literature, the humerus is the most common site for bone metastases of the upper extremity. In our cohort, the percentage undergoing surgery was 57%, which is lower than expected given stabilization of pathologic fractures is pain relieving and considerably lower than the rate of proximal

---

**Table V**

|                          | Intraobserver variability (95% CI) | Strength of agreement |
|--------------------------|-----------------------------------|-----------------------|
| Lesion size              | 0.716 (0.432-0.999)               | Good                  |
| Radiological appearance  | 0.427 (0.195-0.768)               | Moderate              |
| Total Mirels’ score      | 0.580 (0.395-0.765)               | Moderate              |

CI, confidence interval.
femoral lesions undergoing surgery in a comparable cohort (71%, 138/195). In contrast, the overall fracture rate of 76% is considerably higher than that seen in lower limb lesions (57%, 112/195), which may reflect a higher rate of prophylactic fixation in lower limb lesions.

Mortality from referral for upper limb metastases is 29% at 3 months, suggesting there is window of opportunity to assess those patients that may benefit from a prophylactic surgery. The type of surgery is comparable to the literature, with intramedullary nailing being the procedure of choice in most cases as it is reliable for both impending and fractured proximal humerus.

The overall fracture rate of 76% was high, which is in keeping with a lower rate of surgery (therefore, a lower rate of prophylactic fixation) compared to lower limb lesions, although this has been incompletely quantified previously. In addition, the majority of lesions which went on to fracture did so within 3 months (16/20, 80%), emphasizing the importance of the orthopedic referral as a “crisis point” in the clinical progression of a known upper limb metastasis. This also highlights the importance of detection and prediction in a clinical setting to identify those patients early for operative management. It is well documented that patients undergoing elective, prophylactic surgeries for an impending fracture have reduced blood loss, cardiac events, and in-hospital stay compared to those undergoing urgent, emergency surgeries.

Miresl’s score for prediction of metastatic fractures in upper limb metastases

Many previous studies have focused on the validity of the Miresl’s score in predicting metastatic fractures with mixed conclusions regarding the interobserver (reproducibility) and intraobserver (repeatability) variability and predictive value of the score in identifying (A) those who will proceed to fracture and would benefit from surgery (positive predictive value) and (B) those who are unlikely to fracture and should not be subjected to unnecessary surgery (negative predictive value).

Of the studies focusing on the validity of the score in proximal femoral lesions, the most comprehensive is the one by Howard et al, which demonstrated reasonable interobserver and intraobserver variability of the Miresls’ score in predicting pterochanteric fractures. However, they were also unique in assessing for bias and variability among raters and concluded that even in the lower limb, Miresls’ score has poor reproducibility and high subjectivity in predicting fractures.

Mac Niocaill et al preceded this and included long-bone metastases throughout the skeleton. With a similar methodology to our current paper but utilizing only specialist orthopedic oncologists, they found moderate to good variability in radiological aspects of the Miresls’ score in a sample size of 35 radiographs. However, they do not provide data on the number of upper limb lesions included in this series, they did not assess for rater bias, and excluded the pain component of the Miresls’ tool, scoring patients out of a maximum of 9.

The only previous study to assess validity of the Miresls’ score specifically in upper limb metastases was published in 2008 by Evans et al. This study had a relatively small sample size of 17 radiographic lesions assessed by a multidisciplinary group of clinicians and did not assess intraobserver variability. In addition, for interobserver variability, they showed fair agreement for lesion size, moderate for total Miresls’ score, and “incomplete” results for radiographic lesion appearance. As a result, we cannot agree with their conclusion that the Miresls’ score is reproducible and valid for humeral lesions. Of note, they did recommend a reduced Miresls’ cutoff for surgery in upper limb lesions of ≥7/12, in contrast to the recommended cutoff of ≥9/12 for lower limb lesions. This recommendation increased sensitivity of the score in upper limb lesions from 14.5% to 81% with a resultant reduction in specificity from 82.9% to 32%.

We report a similar trade-off with a reduction in the Miresls’ cutoff from ≥9/12 to ≥7/12 (increased sensitivity from 15%-63% with decreased specificity from 73%-55%). We also report a 48% fracture rate with a ≥7/12 Miresls’ cutoff, which is considerably higher than the 33% fracture rate necessitating consideration of prophylactic fixation recommended for lower limbs.

To our knowledge, this is the largest study on this specialist subject to date and the only one that fully evaluates the validity and reproducibility of Miresls’ score in upper limb bony metastases. No previous studies focusing on the prognostic benefit of the Miresls’ score in the upper limb have included as large a patient cohort as ours, nor have they correlated reliability of rater scores with the resultant fracture rate. In addition, we collated scores from a multidisciplinary group of raters, not just orthopedic oncology specialists (as per the original intention of Miresls in reporting the score). Our study is limited, however, in its reliance on retrospective reporting of pain from patient electronic records (introducing potential bias in the total Miresls’ score). In addition, we acknowledge that this patient cohort includes only those patients referred by oncology for a surgical opinion, therefore cannot be assumed to represent all patients with upper limb bone metastases. We acknowledge that rates of fracture may be associated with primary tumor histological diagnosis; this was not specifically explored in the present paper.

Conclusions

We conclude that in patients referred to orthopedics for bone metastases of the upper limb, Miresls’ score may not be valid or reproducible. More importantly, based on the results of our study, we noted that it does not accurately predict risk of progression to pathologic fractures. However, until a more valid scoring system has been developed, we recommend a Miresls’ score threshold of ≥7/12 for consideration of prophylactic fixation of impending upper limb pathologic fractures. A score of ≥7/12 for upper limb long-bone metastases predicts a fracture rate of 48% with sensitivity of 63% and specificity of 55%. This is in contrast to the current threshold of ≥9/12 usually recommended for lower limb lesions.

Disclaimers:

Funding: No funding was disclosed by the authors.
Conflicts of interest: The authors, their immediate families, and any research foundation with which they are affiliated have not received any financial payments or other benefits from any commercial entity related to the subject of this article.

Acknowledgments

This project was undertaken by K.A.H. as part of the Edinburgh Surgical Sciences Qualification, supervised by S.D. and A.C.J.

References

1. Agarwal MG, Nayak P. Management of skeletal metastases: an orthopaedic surgeon’s guide. Indian J Orthop 2015;49:83-100. https://doi.org/10.4103/0019-5413.143915.
2. British Orthopaedic Oncology Society (BOOOS). Metastatic bone disease: a guide to good practice. Available at: http://www.booss.org.uk/wp-content/uploads/2016/03/BOOOS-MBD-2016-BOA.pdf. Accessed November 5, 2022.
3. Choi ES, Han I, Cho HS, Park JW, Park JM, Kim HS. Intramedullary nailing for pathological fractures of the proximal humerus. Clin Orthop Surg 2016;8:458-64. https://doi.org/10.4055/cos.2016.8.4.458.

K.A. Hoban, S. Downie, D.J.A. Adamson et al. JSES International 6 (2022) 675–681
4. Choy WS, Kim KJ, Lee SK, Yang DS, Jeung SW, Choi HG, et al. Surgical treatment of pathological fractures occurring at the proximal femur. Yonsei Med J 2015;56:460-5. https://doi.org/10.3349/ymj.2015.56.2.460.

5. Cohen J. A coefficient of agreement for Nominal Scales. Educ Psychol Meas 1960;20:37-46.

6. Crenn V, Carlier C, Gouin F, Sailhan F, Bonneville P. High rate of fracture in long-bone metastasis: proposal for an improved Mirels predictive score. Orthop Traumatol Surg Res 2020;106:1005-11. https://doi.org/10.1001/jots.2020.03.034.

7. Debartista M, Khodabokus AF, Reynolds J, Horton P, Howarth S, Humphries B, et al. Knowledge and practice of palliative care professionals in prevention of pathological fracture. BMJ Support Palliat Care 2014;4:A71. https://doi.org/10.1136/bmjspcare-2014-000654.201.

8. Dijkstra S, Stapert J, Boxma H, Wiggers T. Treatment of pathological fractures of the humeral shaft due to bone metastases: a comparison of intramedullary locking nail and plate osteosynthesis with adjunctive bone cement. Eur J Surg Oncol 1996;22:621-6.

9. Downie S, Bryden E, Perks F, Simpson HRW. Diagnosis and referral of adults with suspected bony metastases. BMJ 2021;372:n98. https://doi.org/10.1136/bmj.n98.

10. Downie S, Lai FY, Joss J, Adamson D, Jariwala AC. The metastatic early prognostic (MEP) score. Bone Joint J 2020;102-b:72-81. https://doi.org/10.1302/0301-620X.102B1.BJJ-2019-0794.R1.

11. Evans AR, Bottros J, Grant W, Chen BY, Damron TA. Mirels's rating for humerus lesions is both reproducible and valid. Clin Orthop Relat Res 2008;466:1279-84. https://doi.org/10.1097/01.blo.0000093045.56370.d4.

12. Frassica FJ, Frassica DA. Evaluation and treatment of metastases to the humerus. Clin Orthop Relat Res 2003:5212-8. https://doi.org/10.1097/01.blo.0000093052.36273.37.

13. Howard EL, Cool P, Cribb GL. Prediction of pathological fracture in patients with metastatic disease of the lower limb. Sci Rep 2019;9:14133. https://doi.org/10.1038/s41598-019-50636-9.

14. Howard EL, Shepherd KL, Cribb G, Cool P. The validity of the Mirels score for predicting impending pathological fractures of the lower limb. Bone Joint J 2018;100-b:1100-5. https://doi.org/10.1302/0301-620X.100B11.20180313.

15. Kalra A. Decoding the Bland–Altman plot: Basic review. J Pract Cardiovasc Sci 2017;3. https://doi.org/10.4103/jpcs.jpcs_11_17.

16. Khodabokus AFDM, Reynolds J, Horton P, Howarth S, Humphries B, Smith JC. Guidelines for the prevention of pathological fractures in palliative care. Cheshire Merseyside Palliat End Life Care Strategy Clin Netw Stand Guidel 2015 2015.

17. Kronisch C, Balague F, Dudler J. Fear of impending fractures: when to refer? A case-based review. Clin Rheumatol 2015;34:1303-9. https://doi.org/10.1007/s10067-013-2461-4.

18. Mac Niocaill RF, Quinlan JF, Stapleton RD, Hurson B, Dudeney S, O’Toole GC. Inter- and intra-observer variability associated with the use of the Mirels’s scoring system for metastatic bone lesions. Int Orthop 2011;35:83-6. https://doi.org/10.1007/s00264-009-0941-8.

19. Mirels H. Metastatic disease in long bones: a proposed scoring system for diagnosing impending pathologic fractures. 1989. Clin Orthop Relat Res 2003:24-13. https://doi.org/10.1097/01.blo.0000093045.56370.d4.

20. Piccioli A, Spinelli MS, Maccare G. Impending fracture: a difficult diagnosis. Injury 2014;45:3138-41. https://doi.org/10.1016/j.injury.2014.10.038.

21. Ratasvuori M, Wedin R, Keller J, Nottrott M, Zakova O, Bergh P, et al. Insight opinion to surgically treated metastatic bone disease: Scandinavian Sarcoma Group Skeletal Metastasis Registry report of 1195 operated skeletal metastasis. Surg Oncol 2013;22:132-8. https://doi.org/10.1016/j.suronc.2013.02.008.

22. Tatar Z, Soubrier M, Dillies AF, Varelle P, Boisgard S, Lapeyre M. Assessment of the risk factors for impending fractures following radiotherapy for long bone metastases using CT scan-based virtual simulation: a retrospective study. Radiat Oncol 2014;9:227. https://doi.org/10.1186/s13014-014-0227-1.

23. Ward WG, Holsenbeck S, Dorey FJ, Spang J, Howe D. Metastatic disease of the femur: surgical treatment. Clin Orthop Relat Res 2003:5230-44. https://doi.org/10.1097/01.blo.0000093849.72468.82.